<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02216643</url>
  </required_header>
  <id_info>
    <org_study_id>22042613.6.1001.5327</org_study_id>
    <nct_id>NCT02216643</nct_id>
  </id_info>
  <brief_title>EndoVascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke</brief_title>
  <acronym>RESILIENT</acronym>
  <official_title>Randomization of Endovascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke Due to Large VEssel OcclusioN Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>iSchemaView, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brainomix Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, randomized, controlled, open, blinded-endpoint trial with a
      sequential design. The randomization employs a 1:1 ratio of mechanical thrombectomy with
      stentriever and/or Thromboaspiration versus medical management alone. Randomization will be
      done under a minimization process using age, baseline NIHSS, use of IV tpa, vessel occlusion
      site and hospital. To evaluate the hypothesis that mechanical thrombectomy is superior to
      medical management alone in achieving more favorable outcomes in the distribution of the
      modified Rankin Scale scores at 90 days in subjects presenting with acute large vessel
      ischemic stroke &lt;8 hours from symptom onset. Subjects are either ineligible for IV alteplase
      or have received IV alteplase therapy without recanalization. Sample size is projected to be
      690 patients for a difference in treatment effect of 10%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute ischemic stroke related to anterior circulation large vessel occlusion
      will be randomized up to 8 hours from symptoms onset in both arms (mechanical thrombectomy
      versus medical management alone). Subjects are either ineligible for IV alteplase or have
      received IV alteplase therapy without recanalization. They will be admitted at acute stroke
      units in Brazil (or ICU if needed) and treated following international guidelines.
      Concomitant medications and non-pharmacological therapies will be recorded. A maximum of six
      attempts to retrieve the thrombus in a single vessel can be made. No additional treatment
      will be allowed either with Intrarterial tPA, mechanical devices or angioplasty/stenting.

      The primary endpoint will be distribution of the modified Rankin Scale scores at 90 days
      (shift analysis) as evaluated by two separate assessors who are blinded to treatment

      Interim Analysis The sample size for this Phase III Trial is projected to be 690 subjects.
      For interim analyses, the method of Lan and DeMets will be used to allocate alpha via the
      power family method with φ (phi) equal to 1 for the assessment of efficacy and futility,
      respectively after the first 174, 346 and 518 patients enrolled have completed the 90-day
      follow-up. The interval may be more frequent if requested by the Data and Safety Monitoring
      Board (DSMB). At interim analysis, in case the stopping boundaries are crossed the DSMB may
      recommend stopping the study either for better efficacy of the tested treatment either for
      futility. Other factors, such as safety, will be taken into consideration by the DSMB in the
      decision to stop the study. When considering stopping the trial for safety reasons, the DSMB
      will be instructed to consider both mortality (mRS=6) and severe dependency (mRS=5) at 3
      months as one single outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of the modified Rankin Scale scores (shift analysis)</measure>
    <time_frame>90 days</time_frame>
    <description>Distribution of the modified Rankin Scale scores at 90 days (shift analysis) as evaluated by two separate assessors who are blinded to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional independence (modified Rankin Score ≤ 2)</measure>
    <time_frame>90 days</time_frame>
    <description>Functional independence measured by modified Rankin Score ≤ 2 in 90 days in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel recanalization</measure>
    <time_frame>24 hours</time_frame>
    <description>Vessel recanalization evaluated by Computed Tomography angiography or Magnetic Resonance Angiography at 24 hours in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months, 6 months, 1 year</time_frame>
    <description>Quality of life analysis as measured by EuroQol/EQ5D at 3 month, 6 months and one year, between interventional therapy vs medical therapy alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>90 days</time_frame>
    <description>Cost effectiveness analysis of interventional therapy vs medical therapy alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Intracranial hemorrhage</measure>
    <time_frame>24 hours</time_frame>
    <description>Clinically significant Intracranial hemorrhage (ICH) rates at 24 (-2/+12) hours. All intracerebral hemorrhages will be classified by a central core-lab using the ECASS criteria. Symptomatic ICH will be defined as per the SITS-MOST definition: deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in the 22 to 36 hours follow-up imaging scans. The incidence of any asymptomatic hemorrhage measured at 24 (-2/+12) hours will also be compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">690</enrollment>
  <condition>Stroke</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>thrombectomy (Solitaire and/or Penumbra)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mechanical thrombectomy with stentriever Solitaire and/or thromboaspiration with Penumbra System in patients with large vessel occlusion in cerebral anterior circulation vessels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>best medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>best medical treatment in patients with acute ischemic stroke with anterior circulation large vessel occlusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thrombectomy</intervention_name>
    <description>Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire and/or thromboaspiration with Penumbra System versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.</description>
    <arm_group_label>thrombectomy (Solitaire and/or Penumbra)</arm_group_label>
    <other_name>Endovascular treatment</other_name>
    <other_name>Intrarterial treatment</other_name>
    <other_name>Endovascular revascularization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stentriever Solitaire or Penumbra System</intervention_name>
    <description>Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.</description>
    <arm_group_label>thrombectomy (Solitaire and/or Penumbra)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute ischemic stroke where patient is ineligible for IV thrombolytic treatment or the
             treatment is contraindicated (e.g., subject presents beyond recommended time from
             symptom onset), or where patient has received IV thrombolytic therapy without clinical
             improvement.

          2. No significant pre-stroke functional disability (mRS ≤ 1)

          3. Baseline NIHSS score obtained prior to randomization must be equal or higher than 8
             points

          4. Age ≥18 years

          5. Occlusion (TICI 0-1) of the intracranial ICA (distal ICA or T occlusions) and/or
             MCA-M1 segment suitable for endovascular treatment, as evidenced by CTA, MRA or
             angiogram, with or without concomitant cervical carotid occlusion or stenosis.

          6. Patient treatable within eight hours of symptom onset. Symptoms onset is defined as
             point in time the patient was last seen well (at baseline). Treatment start is defined
             as groin puncture.

          7. Informed consent obtained from patient or acceptable patient surrogate

        Exclusion Criteria:

          1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant
             therapy with INR &gt; 3.0

          2. Baseline platelet count &lt; 30.000/µL

          3. Baseline blood glucose of &lt; 50mg/dL or &gt; 400mg/dl

          4. Severe, sustained hypertension (SBP &gt; 185 mm Hg or DBP &gt; 110 mm Hg) NOTE: If the blood
             pressure can be successfully reduced and maintained at the acceptable level using AHA
             guidelines recommended medication (including iv antihypertensive drips), the patient
             can be enrolled.

          5. Patients in coma (NIHSS item of consciousness &gt;1) (Intubated patients for transfer
             could be randomized only in case an NIHSS is obtained by a neurologist prior
             transportation).

          6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS

          7. Serious, advanced, or terminal illness with anticipated life expectancy of less than
             one year.

          8. History of life threatening allergy (more than rash) to contrast medium

          9. Subjects who has received IV t-PA treatment beyond 4,5 hours from the beginning of the
             symptoms

         10. Woman of childbearing potential who is known to be pregnant or lactating or who has a
             positive pregnancy test on admission.

         11. Subject participating in a study involving an investigational drug or device that
             would impact this study.

         12. Cerebral vasculitis

         13. Patients with a pre-existing neurological or psychiatric disease that would confound
             the neurological or functional evaluations, mRS score at baseline must be ≤1. This
             excludes patients who are severely demented, require constant assistance in a nursing
             home type setting or who live at home but are not fully independent in activities of
             daily living (toileting, dressing, eating, cooking and preparing meals, etc.)

         14. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor
             from overseas).

         15. Hypodensity on CT or restricted diffusion amounting to an ASPECTS score of &lt;6 on NCCT,
             or &lt;5 on DWI MRI. The use of CTP or MRI perfusion is optional.

         16. Collaterals with malignant profile on CTA (without colateral circulation on CTA)

         17. CT or MR evidence of hemorrhage (the presence of GRE microbleeds is allowed).

         18. Significant mass effect with midline shift.

         19. Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection
             in the extracranial or petrous segment of the internal carotid artery that cannot be
             treated or will prevent access to the intracranial clot or excessive tortuosity of
             cervical vessels precluding device delivery/deployment

         20. Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior
             circulation, or anterior/posterior circulation)

         21. Evidence of intracranial tumor (except small meningioma).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul Nogueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheila CO Martins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheila CO Martins, PI, MD</last_name>
    <phone>555133598675</phone>
    <email>smartins@portoweb.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raul Nogueira, PI, MD</last_name>
    <email>raul.g.nogueira@emory.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Geral Roberto Santos</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro AP Jesus, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pedro AP Jesus, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre DM Barros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Fortaleza/SUS</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João JF Carvalho, MD</last_name>
      <email>jjcarvalho@gmail.com</email>
    </contact>
    <investigator>
      <last_name>João JF Carvalho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Montalverne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Base do Distrito Federal</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Letícia C Rebello, MD</last_name>
    </contact>
    <investigator>
      <last_name>Letícia C Rebello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno SM Parente, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo S Waihrich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando D Barbosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual Central</name>
      <address>
        <city>Vitória</city>
        <state>Espírito Santo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José A Fiorot Junior, MD</last_name>
    </contact>
    <investigator>
      <last_name>José A Fiorot Junior, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leandro A Barbosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Derval P Pimentel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Bianca Neto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rubia R Sfalsini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elida MN Bassetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas da Universidade Federal do Paraná</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viviane HF Zétola, MD</last_name>
      <email>viviane.zetola@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Viviane FH Zétola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcos Lange, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo C Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São José do Avaí</name>
      <address>
        <city>Itaperuna</city>
        <state>Rio de Janeiro</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivete P Gonçalves, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ivete P Gonçalves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos MP Siqueira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre BP Siqueira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sávio BP Siqueira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romário L Pontes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caio M Pontes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sérgio K Macedo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila CO Martins, MD</last_name>
      <phone>+555133598675</phone>
      <email>smartins@portoweb.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Magda C Martins</last_name>
      <phone>+555133598675</phone>
      <email>mmartins@portoweb.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Sheila CO Martins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosane Brondani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea G Almeida, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gustavo Weiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo E Passos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo F Raupp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario B Faria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Mossmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTENCIA, Hospital São Lucas PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luiz CP Marrone, MD</last_name>
      <email>lcpmarrone@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luiz CP Marrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Raupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Neurologica e Neurocirurgica de Joinville S/S Ltda</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla C Moro, MD</last_name>
      <phone>+554734532118</phone>
    </contact>
    <investigator>
      <last_name>Carla C Moro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Longo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Magalhães, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Governador Celso Ramos</name>
      <address>
        <city>Florianópolis</city>
        <state>SC</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gladys L Martins, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>K</last_name>
    </contact_backup>
    <investigator>
      <last_name>Wuilker K Campos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gladys L Martins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge LW Moritz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando C Freitas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrício Pio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rubens J Gagliardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rubens J Gagliardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mário Conti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gustavo G Provi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rodrigo Bazan, MD</last_name>
      <email>bazan.r@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>Rodrigo Bazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Clayton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li L Min, MD</last_name>
      <email>limin@fcm.unicamp.br</email>
    </contact>
    <investigator>
      <last_name>Li L Min, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonardo Deus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wagner M Avelar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lenise Valer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrício B Cardoso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Ribeirão Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Octavio M Pontes-Neto, MD</last_name>
      <email>octaviopontes@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Octavio M Pontes Neto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Abud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo - UNIFESP/EPM</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gisele S Silva, MD</last_name>
      <email>giselesampaio@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Gisele S Silva, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Laranja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raul Valiente, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darcio Nalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Frudit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2014</study_first_submitted>
  <study_first_submitted_qc>August 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>SHEILA CRISTINA OURIQUES MARTINS</investigator_full_name>
    <investigator_title>MD, PHD, Stroke Neurologist</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Thrombectomy</keyword>
  <keyword>Reperfusion Therapy</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

